FAP and prostate adenocarcinoma: Moreover, lower FAP levels predicted a longer PFI (P = 0.005902) in the TCGA‐PRAD cohort (Figure S16E, Supporting Information), indicating that FAP+ fibroblasts may contribute to PCa progression by creating a niche to promote chemotherapy or radiotherapy resistance.